Suggestions
Chris Claxton
VP of Investor Relations & Marketing at Owlstone Medical
Chris Claxton is a seasoned professional with over 20 years of experience in investor relations, marketing, and corporate development.1 He currently serves as the VP of Investor Relations & Marketing at Owlstone Medical.2
Professional Background
Chris Claxton is recognized for his strategic thinking and dynamic approach to his work.1 His current role at Owlstone Medical involves managing investor relations and marketing efforts for the company.
Key Skills and Expertise
Based on his extensive experience, Chris likely possesses expertise in:
- Investor Relations
- Corporate Marketing
- Strategic Planning
- Corporate Development
Contact Information
While specific contact details are not provided, Chris Claxton's professional profile can be found on LinkedIn under the username "chrisclaxton1".12 For those interested in reaching out professionally, his work email at Owlstone Medical may follow the format c************@owlstone.co.2
Additional Information
It's worth noting that Chris Claxton appears to be a well-established professional in his field. His role as VP of Investor Relations & Marketing suggests he plays a crucial part in Owlstone Medical's communication with investors and overall marketing strategy.
Highlights
Earlier this month at Owlstone we hosted the Annual Breath Biopsy Conference!
The event featured talks from various experts in breath research, offering diverse perspectives. Noteworthy insights were shared by researchers from across the globe, including Professor Robert Rintoul in the United Kingdom and Bruce Johnson from the Mayo Clinic in the United States of America.
For those who couldn't attend, you can catch up on the talks now. Head over to our website to explore the discussions and stay updated on the latest challenges and advancements in the field.
Here’s the link: https://lnkd.in/eb4WgW8Y
Congratulations to Owlstone's hepatology team on the publication 'Exogenous Volatile Organic Compound (EVOC®) Breath Testing Maximizes Classification Performance for Subjects with Cirrhosis and Reveals Signs of Portal Hypertension' in the journal Biomedicines!
You can read more on this important work and our efforts to develop novel screening tests for liver disease here.
